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Abstract
The nonobese diabetic (NOD) Nss1 and Idd5 loci have been
associated with sialadenitis development in mice. In this study
the NOD Nss1 and Idd5 loci were backcrossed onto the healthy
control strain B10.Q by using the speed congenic breeding
strategy, resulting in three congenic strains: B10.Q.Nss1,
B10.Q.Nss1/Idd5  heterozygous and B10.Q.Nss1/Idd5
homozygous. We investigated the effects of the Nss1 and Idd5
loci on sialadenitis and gene expression in NOD congenic mice.
One submandibular salivary gland from each mouse was used
for histological analysis of sialadenitis, whereas the contralateral
salivary gland was used for gene expression profiling with the
Applied Biosystems Mouse Genome Survey chip v.1.0. The
results were validated using quantitative reverse transcriptase
PCR. The NOD Nss1 and Idd5 loci had clear influence on the
onset and progression of sialadenitis in congenic mice. Double
congenic mice exhibited the most severe phenotype. We
successfully identified several genes that are located in the
NOD congenic regions to be differentially expressed between
the congenic strains and the control strain. Several of these
were found to be co-regulated, such as Stat1, complement
component C1q genes and Tlr12. Also, a vast contingency of
interferon-regulated genes (such as Ltb,  Irf7  and  Irf8) and
cytokine and chemokine genes (such as Ccr7 and Ccl19) were
differentially expressed between the congenic strains and the
control strain. Over-representation of inflammatory signalling
pathways was observed among the differentially expressed
genes. We have found that the introgression of the NOD loci
Nss1 and Idd5 on a healthy background caused sialadenitis in
NOD congenic mouse strains, and we propose that genes
within these loci are important factors in the pathogenesis.
Furthermore, gene expression profiling has revealed several
differentially expressed genes within and outside the NOD loci
that are similar to genes found to be differentially expressed in
patients with Sjögren's syndrome, and as such are interesting
candidates for investigation to enhance our understanding of
disease mechanisms and to develop future therapies.
Introduction
Primary Sjögren's syndrome (pSS) is an autoimmune disease
(AID) hallmarked by ocular and oral dryness, known as kerato-
conjunctivitis sicca and xerostomia, respectively. Lymphocytic
infiltrates in the lacrimal and salivary glands (SGs) are promi-
nent features. Sjögren's syndrome can occur alone or second-
ary to other autoimmune connective tissue diseases, such as
rheumatoid arthritis and systemic lupus erythematosus [1].
pSS is considered a multifactorial disease, in which the onset
and progression are invoked by environmental factors in
genetically susceptible individuals. The genetic contribution to
AID = autoimmune disease; CCL = CC chemokine ligand; CCR = CC chemokine receptor; FDR = false discovery rate; MHC = major histocompat-
ibility complex; NOD = nonobese diabetic; PCR = polymerase chain reaction; pSS = primary Sjögren's syndrome; QPCR = quantitative reverse tran-
scriptase PCR; SAM = significance analysis of microarrays; SG = salivary gland; SOCS = suppressor of cytokine signalling; SRI = Sialadenitis Ratio 
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pSS by rates of monozygotic concordance in twins has not yet
been studied, whereas the concordance rate for different
types of AID is ranging from 15% to 60% [2]. Familial cluster-
ing of AID has frequently been reported, and it is common for
a Sjögren's syndrome (SS) proband to have relatives with
other AIDs [3,4]. There is substantial body of evidence sup-
porting an association of SS with the major histocompatibility
complex (MHC) class II region [5,6], but the association with
formation of anti-Ro/La antibodies is stronger than that with
the disease itself for the alleles DRB1*03 and DQB1*02 [6].
Studies conducted to identify polymorphisms in cytokine
genes [7] and other candidate genes associated with SS [3]
have been inconclusive. However, recent gene expression
studies of minor SGs from SS patients have demonstrated
several cytokine genes and interferon-regulated genes to be
upregulated in SS patients compared with control individuals,
indicating that these genes are important players in the pathol-
ogy of SS [8-11].
There is a need to unravel the key mechanisms of onset and
progression of multifactorial AIDs to enhance our understand-
ing and to improve diagnostics and treatment. The search for
underlying mechanisms can be facilitated by reducing the het-
erogeneity of environmental and genetic factors using murine
models of the human condition. The nonobese diabetic (NOD)
mouse, originally introduced to study type 1 diabetes [12], has
been widely used as a model for AIDs. In addition to insulitis
[12], this strain develops SS-like features such as reduced
exocrine function and focal lymphocytic infiltrates in the SGs
[13], and it has become a well established mouse model of SS
[14].
By exchanging the NOD MHC class II allele H2g7 with H2q,
Johansson and coworkers [15] developed a NOD.Q strain
that is protected from type 1 diabetes but exhibits the same
incidence of sialadenitis as the NOD strain [15]. It was con-
cluded that the genes responsible for sialadenitis develop-
ment probably reside outside the MHC region. By linkage
analysis of the (NOD.Q × B10.Q)F2 intercross, in which 9% of
the F2 animals exhibited clear signs of sialadenitis, the Nss1
locus on chromosome 4 was found to be associated with sia-
ladenitis development [15]. Previously, Brayer and coworkers
[16] found the Idd5 locus on chromosome 1 to be linked to
sialadenitis.
The speed congenic breeding strategy was developed to
selectively breed specific loci on the genome and to reduce
genetic heterogeneity between the strains of mice, so that the
only genetic differences between the experimental strain and
the control strain lie within the locus of interest [17]. In the
present study the two NOD loci Idd5 and Nss1 were back-
crossed onto the SS-resistant B10.Q background using the
speed congenic breeding strategy. Three congenic strains
were established: the Nss1  homozygous single congenic
strain; the Nss1 homozygous and Idd5 heterozygous double
congenic strain; and the Nss1  homozygous and Idd5
homozygous double congenic strain.
The purpose of the present study was to monitor the influence
of each of these two loci on the incidence and severity of sia-
ladenitis, and to identify genes located within the NOD loci
that are differentially expressed in submandibular SGs from
the three congenic strains compared with B10.Q (control
strain). We conclude that the Idd5 and Nss1 loci residing out-
side the MHC are sufficient for development of sialadenitis.
Furthermore, we found several genes residing within these
two loci to be differentially expressed, and possibly are impor-
tant factors in the pathogenesis.
Materials and methods
Mice
Congenic strains in the present study are all bred on C57BL/
10 (H2q) (B10.Q) background. The congenic strain for the
Nss1 locus was established by backcrossing the Nss1 region
on chromosome 4 [15] from NOD.Q onto B10.Q using the
speed congenic technique [17] for eight generations and at
the end intercrossed for two generations. Similarly, the Idd5
region on chromosome 1 [16] from the NOD.Q was back-
crossed to the B10.Q background for seven generations and
intercrossed. The double congenic mice were established by
intercrossing seventh generation mice from Nss1 backcross-
breeding and Idd5 breeding, respectively, to generate mice
homozygous at Nss1 in combination with heterozygosity or
homozygosity at Idd5. Genotyping was performed for each
generation. Three congenic strains containing the loci of inter-
est on a B10.Q background were established: B10.Q.Nss1
(homozygous NOD.Q Nss1 locus on a B10.Q background),
B10.Q.Nss1/Idd5-he (homozygous NOD.Q at Nss1, hetero-
zygous for NOD.Q derived Idd5) and B10.Q.Nss1/Idd5-ho
(homozygous NOD.Q at Nss1, homozygous NOD.Q at Idd5).
The NOD fragment Idd5 ranged from 46 to 89 megabases on
chromosome 1 flanked by the markers D1Mit48 and
D1Mit235, and Nss1 ranged from 53 to 140 megabases on
chromosome 4 flanked by the markers D4Mit48 and
D4Mit111, as shown in Figure 1a. The congenic strains were
genotyped across the whole genome to ensure a pure B10.Q
background.
The C57BL/10 (H2q) strain, B10.Q, originated from Professor
Jan Klein (Tübingen, Germany) and was sister-brother main-
tained as the B10.Q/rhd strain. The H2q congenic NOD strain,
NOD.Q, was developed as described previously [15] and
maintained as NOD.Q/rhd.
The mice were bred, kept and used in animal facilities under
standard conditions at the animal unit at Medical Inflammation
Research, University of Lund, Lund, Sweden. The mice were
maintained in a climate controlled environment with a 12-hour
light/dark cycle in polystyrene cages containing wood shav-Available online http://arthritis-research.com/content/9/5/R99
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ings; they were fed with standard rodent chow and were given
free access to water (as defined by Medical Inflammation
Research [18]). All animal experiments were approved by the
local ethics committee in Malmö-Lund.
Evaluation of incidence and severity of sialadenitis
The mice were killed at age 16 to 19 weeks, and the pairs of
submandibular SGs were removed. One SG from each mouse
was frozen in RNAlater (Ambion, Austin, TX, USA) for subse-
quent gene expression analysis, whereas the other was
embedded in TissueTek® (Sakura Finetek USA, Inc., Torrance,
CA, USA), snap frozen in liquid nitrogen and kept at -80°C
until later haematoxylin and eosin staining. Tissue sections
(6.0 μm thick) were prepared in a cryostat at -20°C. The sec-
tions were dried and fixed in 50% cold acetone (4°C) for 30
seconds, followed by 100% acetone (4°C) for 5 minutes. After
air drying (1 minute), the slide was submerged in haematoxylin
for 25 seconds, washed in water, submerged in eosin for 20
seconds, and washed in ethanol and cold toluene for 5 min-
utes. After short evaporation, cover glass was mounted with
two drops of Eukitt (Kindler Gmbh & Co., Freiburg, Germany).
The foci, defined as inflammatory mononuclear cell infiltrates
with more than 50 mononuclear cells/mm2 of the submandib-
ular SG section [19], were identified and the severity of inflam-
mation was determined by calculating the focus area relative
to the total area of the gland [15]. The differences in inflamma-
tion between the congenic strains and the control strain were
examined for statistical significance by using one-way analysis
of variance with a two-tailed Dunnet's post hoc test at a signif-
icance level of 0.05.
Preparation of total RNA
The SGs frozen in RNAlater were divided in two and homoge-
nized, first manually in liquid nitrogen and thereafter in 350 μl
RLT buffer from the RNeasy MiniKit (Qiagen Inc., Valencia,
CA, USA) was added to the tissue powder and the sample
was homogenized in a Kinematica Polytron homogenizer
(Brinkman, Westbury, NY, USA) for 1 minute, and the RNeasy
MiniKit was used for RNA purification (as described by the
manufacturer). The RNA was eluted in 60 μl RNase free water
and precipitated with white glycogen, as described by Hjelm-
ervik and coworkers [8]. The RNA quality was examined on the
2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA).
All samples included high amounts (from 2 to 5 μg/μl) of good
quality RNA.
Salivary gland gene expression
The total RNA was submitted to the RNA-in/data-out service
of the Norwegian Microarray Consortium Core Facility in Ber-
gen, Norway. The labeling of 1.0 μg total RNA for each individ-
ual was done according to the NanoAmp™ RT-IVT Labeling Kit
protocol (Applied Biosystems [ABI], Foster City, CA, USA).
The cDNA was purified and subjected to IVT labeling at 37°C
for 9 hours. The digoxigenin (DIG)-labeled cRNA was purified
using the columns supplied with the kit and eluted in 100 μl
Figure 1
Congenic regions and incidence of sialadenitis in congenic mice and  healthy controls Congenic regions and incidence of sialadenitis in congenic mice and 
healthy controls. (a) The location of the two nonobese diabetic (NOD) 
fragments Idd5 and Nss1 on chromosome (Chr.) 1 and Chr. 4, respec-
tively. (b) The severity of sialadenitis, represented by the Sialadenitis 
Ratio Index (SRI), which is the total focus area (mm2) divided by the 
total gland area (mm2). The strains are B10.Q (n = 10), B10.Q.Nss1 
(NB; n = 4), B10.Q.Nss1/Idd5-he (NBI-he; n = 4) and B10.Q.Nss1/
Idd5-ho (NBI-ho; n = 7). The numbers and each of the bars represent 
mean values of SRI for each group, the error bars show standard error 
of the mean, and statistically significant increase compared with B10.Q 
is indicated by asterisk (analysis of variance with Dunnet's post hoc 
test; P = 0.017).Arthritis Research & Therapy    Vol 9 No 5    Hjelmervik et al.
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nuclease free water. The yield and quality of the labeled cRNA
was measured at an absorbance of 260 nm.
The DIG labeled cRNA was fragmented, hybridized to ABI
Mouse Genome Survey chip v.1.0 and scanned in accordance
with the ABI Chemiluminescence detection kit protocol.
Data processing and statistical analysis
The gene expression data was analyzed using J-Express Pro
2.7 (Molmine, Bergen, Norway [20]). All of the microarray pro-
cedure was MIAME (Minimum Information About a Microarray
Experiment) compliant. The microarray data were deposited in
the ArrayExpress repository with the accession number E-
BASE-6 [21].
Pre-processing 1: filtration and normalization of microarray 
data
The data files from the ABI Mouse Genome Survey microarray
v.1.0 were processed using J-Express Pro to filter and normal-
ize the data from each hybridization and compile gene expres-
sion profile matrix (gene by sample) datasets for further
analysis. The pre-normalized intensity values were extracted
per spot (ASSAY_NORMALIZED_SIGNAL) from the data
files, and all flagged, weak and control spots were filtered out
(FLAGS > 1.0, S/N < 3.0, PROBE_TYPE != probe). Before
they were compiled into an expression profile data matrix, all
arrays were quantile normalized in order to be comparable.
Genes with at most 15% missing values were allowed in the
final dataset. The signal intensities in the dataset were further
log transformed (base 2), and missing values were replaced by
the average of nearest rows neighbour values. One individual,
B10.Q.Nss1/Idd5-ho 11, was found to be an outlier in both
the array plot and the correspondence analysis in J-Express,
and was excluded from the raw dataset, before filtration and
normalization. The resulting gene expression matrix was used
in the 'standard analysis'.
Alternative analysis: selecting for genes with standard 
deviation >0.7
The raw data were processed with the same parameters as in
pre-processing 1, except for the S_N > 3 filter. After log2
transforming the intensities, replacing missing values and col-
lapsing probes to genes, the gene lists were filtered by mini-
mum standard deviation = 0.7. Finally, the genes in the list
'pre-processing 1' were removed. The resulting gene expres-
sion matrix was used for the 'alternative analysis'.
Differentially expressed gene analysis
The search for differentially expressed genes was performed
both on a single gene and gene set level. The significance
analysis of microarrays (SAM) [22] implementation in J-
Express was used to look for differentially expressed genes on
a gene by gene basis, whereas gene set enrichment analysis
(GSEA) [23] was used to look for sets of genes, sharing com-
mon characteristics, that were differentially expressed
between the classes examined.
Compilation of gene sets
Gene sets were created using the Panther Biological Process
and Panther Molecular Function, extracted from the Applied
Biosystems Mouse Annotation File, dated 12 December
2005. The hierarchy of the Panther ontologies has at most
three levels. We created one gene set for each of the biologi-
cal processes and molecular functions, on all levels. The gene
sets at the finest level contains only the genes annotated to
this particular process or function, whereas a parent process
or function contains all genes annotated to this level plus all
the genes annotated to its children. All probes listed in the
annotation file are annotated to all levels, which enabled us to
create complete gene sets in a straight forward manner. This
yielded 238 gene sets based on Panther Biological Processes
and 251 gene sets based on Panther Molecular Functions.
Parameters of GSEA
Probes were collapsed to genes, using Primary Gene Id from
the ABI Mouse Annotation File, before running GSEA. Gene
sets smaller than five were excluded from the analysis. The
default signal to noise ratio metric was used to rank the genes.
Significance of the gene set analysis was tested by permuting
class labels (1,000 iterations). Default values were also used
for all other parameters.
Pathway search
The lists of differentially expressed genes from the 'standard
analysis' and 'alternative analysis' were combined for each
comparison, and the 'Probe Id' for each gene was applied in
the pathway search in the Panther Classification System [24].
The Mouse AB 1700 gene list, representing all the genes on
the microarray, was used as reference gene list and Bonferroni
correction for multiple testing was applied.
Verification of the microarray results by quantitative 
reverse transcriptase PCR
The quantitative reverse transcriptase PCR (QPCR) was car-
ried out in all individuals in each group, using the same extract
of total RNA as used for the microarrays. The cDNA was syn-
thesized in volumes of 50 μl according to the recommenda-
tions for the TaqMan Reverse Transcriptase kit (ABI). The
reverse transcription of total RNA was carried out as
described by Bolstad and colleagues [10]. The cDNA was
kept at -20°C until use. Genes for verification of the microarray
results by QPCR were selected from among the genes differ-
entially expressed between congenic strains and control
strain, from the gene lists of both standard and alternative anal-
yses. Primers and probes were purchased as TaqMan®
Assays-on-Demand™ Gene Expression Products (ABI). These
are pre-formulated assays (250 μl, 20× mix) containing two
unlabelled PCR primers and one FAM™ dye-labelled TaqMan®
MGB probe each. The 10 assays used for QPCR validationAvailable online http://arthritis-research.com/content/9/5/R99
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were Ccl19 (Mm00839967_g1), Cd19 (Mm00515420_m1),
Egf (Mm00438696_m1), Klk9 (Egf-bp) (Mm00658534_mH),
Ltb  (Mm00434774_g1),  Sell  (Mm00441291_m1),  Zap70
(Mm00494255_m1),  Stat1  (Mm00439518_m1),  Dock7
(Mm01259863_m1) and Fas  (Mm00433237_m1). The
cDNA was mixed with the TaqMan® Assays-on-Demand™
primers and probe in a 2× TaqMan Universal Master Mix (ABI)
and run in 10 μl triplicate PCR in a 384-well tray (ABI). The
endogenous controls Gapdh, β-actin and 18s were run on all
samples, and Gapdh was used for normalizing the total RNA
added in each reaction. The ΔΔCt method was used to calcu-
late relative mRNA level, and statistically significant differ-
ences were determined using the two tailed Student's t-test,
at a significance level of 0.05. For each assay, one reaction
without Multiscribe RT enzyme was included, to ensure RNA
specificity of the assays.
Results
Influence of NOD Idd5 and Nss1 loci on severity of 
sialadenitis
Ten mice of the control strain B10.Q and mice from three con-
genic strains, namely B10.Q.Nss1 (n = 4), B10.Q.Nss1/Idd5-
he (n = 4) and B10.Q.Nss1/Idd5-ho (n = 7), all of which were
female, were killed at age 16 to 19 weeks, and the submandib-
ular SGs were removed. All mice appeared healthy upon visual
inspection.
Histological examination of the SGs demonstrated the severity
of sialadenitis to be increased with NOD loci introduced to the
B10.Q background, as shown in Figure 1b. The control mice
had none or in some cases one minor focal infiltrate, whereas
the number and the severity of infiltrates in the NOD congenic
mice increased considerably. In order to assess the effect that
addition of each NOD locus to the B10.Q background exerted
on sialadenitis in the mice, the mean focus area over total
gland area (termed Sialadenitis Ratio Index [SRI]), was calcu-
lated for each strain of congenic mice and compared with that
of the control strain. The B10.Q.Nss1 strain (n = 4) and the
B10.Q.Nss1/Idd5-he strain (n  = 4) had an increased SRI
compared with the control strain, although not statistically sig-
nificantly so. The B10.Q.Nss1/Idd5-ho strain (n = 7) exhibited
the most severe sialadenitis, and the SRI was found to be sig-
nificantly increased compared with the B10.Q strain (n = 10)
by analysis of variance with Dunnet's post hoc test (P  =
0.017).
Gene expression differences between the congenic mice 
and the control strain
The contralateral submandibular SG of each animal was used
for gene expression profiling. Initially, we observed a high
degree of similarity in the gene expression from the strains of
mice heterozygous or homozygous for the Idd5 locus (there
were no differentially expressed genes). The two strains
B10.Q.Nss1/Idd5-he and B10.Q.Nss1/Idd5-ho were there-
fore grouped to enhance the power of the gene expression
analysis. The double congenic mice as one group of mice
were denoted B10.Q.Nss1/Idd5.
The analysis was focused mainly on differentially expressed
genes from three comparisons: B10.Q versus B10.Q.Nss1,
B10.Q versus B10.Q.Nss1/Idd5, and B10.Q.Nss1  versus
B10.Q.Nss1/Idd5. The SAM algorithm was run on the com-
parisons and gene lists were created based on a false discov-
ery rate (FDR) of less than 10% for the standard analysis gene
list (genes with a signal to noise ratio >3 in all samples) and
FDR less than 20% for the alternative analysis gene list (hyper-
variable genes with minimum standard deviation >0.7). In com-
paring the gene expression of the congenic strains with that of
the control strains, the standard analysis elicited gene lists of
2,435 differentially expressed genes for B10.Q versus
B10.Q.Nss1/Idd5 and 1,411 differentially expressed genes
for B10.Q versus B10.Q.Nss1 and 255 and 78, respectively,
differentially expressed genes from the alternative analysis.
Therefore, 10% to 20% of the expressed genes (remaining
after pre-processing the data) were differentially expressed
between the congenic mice and the control mice. For
B10.Q.Nss1 versus B10.Q.Nss1/Idd5, only 192 genes from
the standard analysis and 51 genes from the alternative analy-
sis were differentially expressed. Thus, 2% of the expressed
genes were differentially expressed when comparing the sin-
gle congenic with the double congenic mice.
Quantitative PCR validation of gene expression data
Genes were selected from the gene lists of the standard and
alternative analyses in order to verify the microarray results
using QPCR. Only genes with FDR below 60% in at least one
of the three gene lists were selected. Table 1 shows the genes
selected for QPCR and displays the fold change from the
microarray and QPCR as a mean of all individuals in the
respective groups.
All gene expression quantifications obtained in the QPCR
were in accordance with results from the microarray. The
B10.Q versus B10.Q.Nss1 gene list was verified by seven
genes, four that were upregulated and three that were down-
regulated in B10.Q.Nss1, at a significance level of 0.05. Fur-
thermore, two genes were found upregulated by QPCR. The
B10.Q versus B10.Q.Nss1/Idd5  gene list was verified by
seven genes, six of which were upregulated in B10.Q.Nss1/
Idd5. Furthermore, two genes were found to be downregu-
lated and one upregulated. For B10.Q.Nss1  versus
B10.Q.Nss1/Idd5, two genes verified the microarray data,
both of which were upregulated in B10.Q.Nss1/Idd5; these
genes were the only two with FDR below 60% for this gene
list. Additionally, five of the genes were upregulated as on the
microarray.
Gene graph analysis and K-means clustering
Although the congenic mice varied genetically from the control
strain at only one or two NOD loci, there was a substantial dif-Arthritis Research & Therapy    Vol 9 No 5    Hjelmervik et al.
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ference in gene expression. This was convincingly demon-
strated in that the top differentially expressed genes with a
FDR of 0.0 (no false positive in the gene list) had distinct gene
profiles that distinguished the control mice from the congenic
mice. These gene graphs are presented in Figure 2a–f for both
the standard and alternative analyses. The number of genes
with no FDR and consistent expression within the groups illus-
trate that the dataset is robust, and that the NOD loci are able
to induce a consistent influence on the gene expression.
Among the top differentially expressed genes (FDR = 0.0),
there was an even distribution of upregulated and downregu-
lated genes. This clustering shows that the gene expression
data are robust and provide clear differences between the
strains.
Gene expression differences of genes located in the 
NOD loci Idd5 and Nss1
The main focus of the gene expression profiling has been on
identifying genes in the two NOD derived congenic regions
Idd5 and Nss1 that clearly cause the increase in sialadenitis in
the congenic mice compared with the control strain. Differen-
tially expressed genes within the congenic regions for each of
the three gene list are presented in Table 2.
Usually, one will find that the expression of some genes
located in the same chromosomal regions and contributing in
the same process is co-regulated. In order to identify genes in
the Idd5 and Nss1 loci that are co-regulated, the differentially
expressed genes from (within) the two loci were subjected to
K-means clustering. Thus, 91 genes from the comparison
B10.Q versus B10.Q.Nss1 and 131 genes from the compari-
son B10.Qversus B10.Q.Nss1/Idd5 were clustered into five
clusters for each comparison. We identified a set of genes that
clustered together in both comparisons (Figure 2g,h), namely
Stat1, Fn1, Cd52, Col16a1, Laptm5 and Sdc3, and the com-
plement component 1 genes C1qb, C1qa and C1qg.
Located in the Nss1 locus, Lck and Tlr12 were among the
most highly upregulated genes in B10.Q.Nss1/Idd5  com-
pared with B10.Q, and Ifnz  was downregulated in
B10.Q.Nss1/Idd5 compared with B10.Q.Nss1.
Furthermore, from Table 2 it can be concluded that a majority
of the genes from the Nss1 region are common between the
gene lists (34 out of 47 genes), whereas only two out of eight
genes in the Idd5 region are common. This can be explained
by that the Nss1 region in both congenic strains was similarly
NOD derived, whereas the Idd5 region differed between the
single and double congenic strains, and we therefore saw
more diverse gene expression from this region.
Among the most highly differentially expressed genes, we
found 24-dehydrocholesterol reductase (Dhcr24), transmem-
brane protein 54 (Tmem54), coiled coil domain containing
28B (Ccdc28b) and testis-specific serine kinase 3 (Tssk3) all
to be downregulated. Furthermore, we found zink finger and
BTB domain containing 8 (Zbtb8) and zink finger protein 69
(Zfp69) genes to be among the most highly upregulated in the
congenic mice.
Differentially expressed immunity related genes
In breeding the congenic strains, great care was taken only to
transfer the designated NOD fragments Idd5 and Nss1 to the
B10.Q background. However, passenger genes may travel
Table 1
Validation of microarray by QPCR
Gene symbol B10.Q versus B10.Q.Nss1 B10.Q versus B10.Q.Nss1/Idd5 B10.Q.Nss1 versus B10.Q.Nss1/Idd5
Array FC QPCR FC QPCR P value Array FC QPCR FC QPCR P value Array FC QPCR FC QPCR P value
Ltb 2 2.4 0.03 2.7 4.3 0.01 1.3 1.8 0.25
Egf -3 -5.9 0.04 -1.9 -1.6 0.17 1.6 3.5 0.01
Ccl19 2.7 2.5 < 0.01 3.3 8.6 0.01 1.2 3.5 0.17
Klk9 -2.2 -5.0 0.03 -1.4 -1.3 0.44 1.5 3.8 < 0.01
Stat1 2.2 1.3 0.3 1.8 1.6 0.03 -1.3 1.3 0.28
Zap70 2.8 2.5 < 0.01 2.4 3.6 0.02 1.1 1.5 0.34
Cd19 3.1 5.4 0.02 3.5 20.9 0.04 1.2 3.9 0.25
Sell - - - 3 9.2 0.09 2.7 3.7 0.25
Dock7 -1.6 -1.9 < 0.01 -1.8 -1.6 < 0.01 -1.1 1.2 0.2
Fas 2.3 1.2 0.34 2 1.5 0.01 - - -
The three columns under each comparison (gene list) represent, from left to right, the fold change (FC) from the microarray gene list, the FC for the 
quantitative reverse transcriptase PCR (QPCR) and the statistical significance from the QPCR (P value). Genes with positive FC were 
upregulated in the congenic mice compared with B10.Q, and upregulated in B10.Q.Nss1/Idd5 when compared with B10.Q.Nss1. The genes Ltb, 
Egf, Ccl19, Klk9 and Stat1 were selected from the gene list of the standard analysis, and Zap70, Cd19, Sell, Dock7 and Fas were selected from 
the gene list of the alternative analysis.Available online http://arthritis-research.com/content/9/5/R99
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Figure 2
Genes differentially expressed in congenic mice compared to healthy controls Genes differentially expressed in congenic mice compared to healthy controls. Panels a to f show gene graphs of genes differentially expressed with 
false discovery rate of 0.0: (a) B10.Q versus NB, 'standard analysis' (71 genes); (b) B10.Q versus NB, 'alternative analysis' (8 genes); (c) B10.Q 
versus NBI, 'standard analysis' (271 genes); (d) B10.Q versus NBI, 'alternative analysis' (61 genes); (e) NB versus NBI, 'standard analysis' (59 
genes); and (f) NB versus NBI, 'alternative analysis' (19 genes). Upregulated and downregulated genes in the congenic mice are presented by red 
and green lines, respectively. The genes within the nonobese diabetic (NOD) congenic fragments on the lists of differentially expressed genes were 
selected and clustered by K-means clustering to identify co-regulation of genes within the fragments. Also presented are differentially expressed 
genes in fragments Idd5 (blue) and Nss1 (black) for the (g) B10.Q versus NB and (h) B10.Q versus NBI comparisons. The gene expression values 
are log2 transformed and mean normalized. The abscissa indicates the individual mice and the ordinate shows the gene expression intensities. The 
congenic mice are denoted NB (B10.Q.Nss1) and NBI (B10.Q.Nss1/Idd5-he and B10.Q.Nss1/Idd5-ho).Arthritis Research & Therapy    Vol 9 No 5    Hjelmervik et al.
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Table 2
Differentially expressed genes in the two congenic intervals
Gene ID Gene symbola Gene name Fold changeb
B10.Q versus NB B10.Q versus NBI NB versus NBI
215627 Zbtb8 Zinc finger and BTB domain containing 8 3.7 4.4
384059 Tlr12 Toll-like receptor 12 3.3
381549 Zfp69 Zinc finger protein 69 3.2 3.3
230779 Serinc2 Serine incorporator 2 3 2.2
16818 Lck Lymphocyte protein tyrosine kinase 2.9 3
12260 C1qb Complement component 1, q subcomponent, beta 
polypeptide
2.8 1.8
23833 Cd52 CD52 antigen 2.5 2
12259 C1qa Complement component 1, q subcomponent, alpha 
polypeptide
2.4 1.7
20846 Stat1 Signal transducer and activator of transcription 1 2.2 1.8
14268 Fn1 Fibronectin 1 2.2 1.7
14612 Gja4 Gap junction membrane channel protein alpha 4 2.2
18991 Pou3f1 POU domain, class 3, transcription factor 1 2.2
11520 Adfp Adipose differentiation related protein 2.1 1.7
107581 Col16a1 Procollagen, type XVI, alpha 1 2.1 1.6
269582 Clspn Claspin homolog (Xenopus laevis) 2.1
16792 Laptm5 Lysosomal-associated protein transmembrane 5 1.9 1.8
12579 Cdkn2b Cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) 1.9 1.6
20970 Sdc3 Syndecan 3 1.9 1.6
20720 Serpine2 Serine (or cysteine) peptidase inhibitor, clade E, member 2 1.8
14700 Gng10 Guanine nucleotide binding protein (G protein), gamma 10 1.8
230657 Tmem69 Transmembrane protein 69 1.7 1.5
16008 Igfbp2 Insulin-like growth factor binding protein 2 1.7
73723 Sh3bgrl3 SH3 domain binding glutamic acid-rich protein-like 3 1.7
93691 Klf7 Kruppel-like factor 7 (ubiquitous) 1.6 -1.6
66290 Atp6v1g1 ATPase, H+ transporting, V1 subunit G isoform 1 1.6
27981 D4Wsu53e DNA segment, Chr 4, Wayne State University 53, 
expressed
1.6
17965 Nbl1 Neuroblastoma, suppression of tumorigenicity 1 1.6
67103 Ltb4dh Leukotriene B4 12-hydroxydehydrogenase 1.6
230379 Asah3l N-acylsphingosine amidohydrolase 3-like 1.6
19231 Ptma Prothymosin alpha 1.5
68777 Tmem53 Transmembrane protein 53 1.5
320438 Alg6 Asparagine-linked glycosylation 6 homolog (yeast, alpha-
1,3,-glucosyltransferase)
1.5
101739 Psip1 PC4 and SFRS1 interacting protein 1 1.5
230861 Eif4g3 Eukaryotic translation initiation factor 4 gamma, 3 -1.5 -1.7
74648 S100pbp S100P binding protein -1.5Available online http://arthritis-research.com/content/9/5/R99
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with the NOD fragments. Additionally, the genes within the
NOD fragments may affect gene expression elsewhere in the
genome. We therefore looked for differentially expressed
genes outside the NOD fragments, especially genes related to
inflammation.
In the B10.Q versus B10.Q.Nss1 gene list of 1,411 differen-
tially expressed genes, 20 interferon-regulated genes, includ-
ing Ifnγ, and 16 out of 16 MHC genes (classes I and II) were
all upregulated in B10.Q.Nss1. The Tlr2, Tlr5 and Tlr12 genes
(encoding Toll-like receptors 2, 5 and 12), as well as several
complement component 1 genes, were upregulated in
B10.Q.Nss1.
The B10.Q vs B10.Q.Nss1/Idd5 comparison also exhibited
several interferon-regulated genes, of which 29 out of 30 were
upregulated and 18 out of 18 MHC genes were upregulated.
Tlr2  was upregulated in B10.Q.Nss1/Idd5. In both
B10.Q.Nss1 and B10.Q.Nss1/Idd5, the gene encoding Toll-
interleukin1 receptor domain containing adapter (Tirap1) was
downregulated compared with B10.Q.
Several other cytokines and chemokines were upregulated in
the congenic mice compared with the control strain, as listed
in Table 3. In B10.Q.Nss1/Idd5, 18 chemokines and seven
cytokines were differentially expressed, and in B10.Q.Nss1 13
chemokines and eight cytokines were upregulated. Several
chemokines, among these lymphotoxin β ( Ltb),  Cxcl13,
Cxcl16 and Ccl19, and the cytokines Socs1 and Socs3 were
commonly upregulated in both B10.Q versus B10.Q.Nss1
and B10.Q versus B10.Q.Nss1/Idd5 gene lists. There were
no cytokines or chemokines identified as being differentially
expressed between the two congenic strains B10.Q.Nss1
and B10.Q.Nss1/Idd5.
Gene set enrichment analysis
Thus far the gene expression analysis has been based on gene
lists with differentially expressed single genes (where the
focus is often on the most highly differentially expressed genes
or on genes implicated beforehand). In order to look for more
subtle gene expression changes than the highest ranking dif-
ferentially expressed genes, and to identify molecular and bio-
logical processes where several genes are involved in the
101739 Psip1 PC4 and SFRS1 interacting protein 1 -1.5
18710 Pik3r3 Phosphatidylinositol 3 kinase, regulatory subunit, 
polypeptide 3 (p55)
-1.5
67694 Ift74 Intraflagellar transport 74 homolog (Chlamydomonas) -1.5
76850 Eif2c4 Eukaryotic translation initiation factor 2C, 4 -1.5
19359 Rad23b RAD23b homolog (S. cerevisiae) -1.5 -1.8
319146 Ifnz Interferon zeta -1.5
100206 Adprhl2 ADP-ribosylhydrolase like 2 -1.6 -1.7
230815 Man1c1 Mannosidase, alpha, class 1C, member 1 -1.6
67299 Dock7 Dedicator of cytokinesis 7 -1.6 -1.8
21885 Tle1 Transducin-like enhancer of split 1, homolog of Drosophila 
E(spl)
-1.7
66902 Mtap Methylthioadenosine phosphorylase -1.8
11363 Acadl Acetyl-coenzyme A dehydrogenase, long-chain -1.8
71872 Aox4 Aldehyde oxidase 4 -1.9
236511 Eif2c1 Eukaryotic translation initiation factor 2C, 1 -2.1 -1.8
58864 Tssk3 Testis-specific serine kinase 3 -3.2
13370 Dio1 Deiodinase, iodothyronine, type I -3.4 -2.3
66264 Ccdc28b Coiled coil domain containing 28B -4.2 -4.3
66260 Tmem54 Transmembrane protein 54 -5 -8
74754 Dhcr24 24-Dehydrocholesterol reductase -12.7 -13.8
aGenes on chromosome 1 (Idd5) lie within the markers D1Mit48 and D1Mit235, and genes on chromosome 4 (Nss1) lie within the markers 
D4Mit48 and D4Mit111. Genes with underlined gene symbols are in the Idd5 fragment. Unknown expressed sequence tags and genes with fold 
change < ± 1.5 were removed. bThe fold change is the relative intensities for each gene from the microarray gene lists B10.Q versus B10.Q.Nss1, 
B10.Q versus B10.Q.Nss1/Idd5 and B10.Q.Nss1 versus B10.Q.Nss1/Idd5, respectively. Genes with positive fold change were upregulated in 
the congenic mice, and in B10.Q.Nss1/Idd5 when compared with B10.Q.Nss1. NB, B10.Q.Nss1; NBI, B10.Q.Nss1/Idd5-he and B10.Q.Nss1/
Idd5-ho.
Table 2 (Continued)
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same process, gene sets were generated and the GSEA was
carried out.
GSEA was based on gene lists from the four comparisons
(B10.Q versus B10.Q.Nss1, B10.Q versus B10.Q.Nss1/
Idd5, B10.Q.Nss1  versus B10.Q.Nss1/Idd5  and
B10.Q.Nss1/Idd5-he versus B10.Q.Nss1/Idd5-ho), with all of
the genes remaining after the 'signal to noise' filtration in 'pre-
processing 1'. Gene sets with a FDR below 25%, correspond-
ing to each normalized enrichment score [23], are considered
significantly enriched in the gene lists.
From the 'Biological processes' branch of the Gene Ontology,
the gene set 'Other carbon metabolism' was significantly
enriched in B10.Q.Nss1/Idd5-he compared with
B10.Q.Nss1/Idd5-ho, and several carbonic anhydrase genes
contributed positively to the enrichment score.
Several gene sets were enriched with a level of significance of
1% (GSEA nominal P  value) in B10.Q.Nss1  and
B10.Q.Nss1/Idd5 compared with B10.Q, such as 'Chemok-
ine mediated immunity', 'Macrophage mediated immunity', 'T-
cell and B-cell mediated immunity' and 'Immunity and defense'.
This trend was further heavily supported by the fact that 10 out
of the 12 gene sets (out of 238) related to 'Immunity' were
among the top 14 ranking gene sets in the B10.Q versus
B10.Q.Nss1/Idd5 comparison.
Table 3
Differentially expressed cytokine and chemokine genes
Gene ID Gene symbol Gene name Fold changea
B10.Q versus NB B10.Q versus NBI
55985 Cxcl13 Chemokine (C-X-C motif) ligand 13 4.3 4.8
17329 Cxcl9 Chemokine (C-X-C motif) ligand 9 4.2 3.1
20307 Ccl8 Chemokine (C-C motif) ligand 8 3.6 3
20304 Ccl5 Chemokine (C-C motif) ligand 5 3 2.3
20305 Ccl6 Chemokine (C-C motif) ligand 6 2.9 2
24047 Ccl19 Chemokine (C-C motif) ligand 19 2.7 3.3
12772 Ccr2 Chemokine (C-C motif) receptor 2 2.5 1.7
12766 Cxcr3 Chemokine (C-X-C motif) receptor 3 2.3 2.2
66102 Cxcl16 Chemokine (C-X-C motif) ligand 16 2.3 1.5
12702 Socs3 Suppressor of cytokine signalling 3 2.1 2
450136 Ltb Lymphotoxin B 2 2.7
20308 Ccl9 Chemokine (C-C motif) ligand 9 2 1.5
12703 Socs1 Suppressor of cytokine signalling 1 2 1.6
12774 Ccr5 Chemokine (C-C motif) receptor 5 2 1.5
75974 Dock11 Dedicator of cytokinesis 11 1.8 1.8
67299 Dock7 Dedicator of cytokinesis 7 -1.6 -1.8
109006 Ciapin1 Cytokine induced apoptosis inhibitor 1 -1.5 -1.3
20315 Cxcl12 Chemokine (C-X-C motif) ligand 12 1.4 1.4
57266 Cxcl14 Chemokine (C-X-C motif) ligand 14 1.4 1.2
20292 Ccl11 Small chemokine (C-C motif) ligand 11 1.3 1.4
54199 Ccrl2 Chemokine (C-C motif) receptor-like 2 1.3 1.2
56066 Cxcl11 Chemokine (C-X-C motif) ligand 11 2.4
12775 Ccr7 Chemokine (C-C motif) receptor 7 2.3
12767 Cxcr4 Chemokine (C-X-C motif) receptor 4 2
aThe fold change is the relative intensities for each gene from the microarray gene lists B10.Q versus B10.Q.Nss1 and B10.Q versus 
B10.Q.Nss1/Idd5. Genes with positive fold change were upregulated in the congenic mice. Genes with fold change <1.3 were removed. NB, 
B10.Q.Nss1; NBI, B10.Q.Nss1/Idd5-he and B10.Q.Nss1/Idd5-ho.Available online http://arthritis-research.com/content/9/5/R99
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Pathway search
In order to have any impact on the biological process in the
SG, several genes in the same signalling pathway are usually
expressed simultaneously. If several genes in our gene list
belong to the same pathway, then this pathway is likely to be
important for the biological processes that take place in the
SG, and therefore these genes may be amenable for further
investigation as candidates for therapeutic intervention.
The lists with differentially expressed genes resulting from
gene expression profiling were therefore submitted to a Pan-
ther database search in order to identify signalling pathways
over-represented in the gene lists. Three pathways were over-
represented in both the B10.Q versus B10.Q.Nss1 and the
B10.Q versus B10.Q.Nss1/Idd5 gene lists: 'T-cell activation',
'Inflammation mediated by cytokine and chemokine signalling
pathway', and 'B-cell activation'. In addition, the 'Interferon-
gamma signalling pathway' was over-represented in B10.Q
versus B10.Q.Nss1. Genes in the 'Toll-like receptor signalling
pathway' were over-represented, but not significantly so at a
significance level of 0.05 after Bonferroni correction for multi-
ple testing (in this case 131 signalling pathways). Parts of
three pathways are displayed in Figure 3.
Discussion
This study was conducted in order to monitor the effect of the
two NOD fragments Idd5 and Nss1 on sialadenitis develop-
ment and to identify genes in the two loci associated with the
development of sialadenitis in the congenic mice.
All the congenic strains had higher SRI values than the control
strain, although not all of these were significant. The NOD
congenic mouse strain homozygous in both Nss1 and Idd5
loci (NBI-ho) had the most severe sialadenitis. The introgres-
sion of only the NOD-Nss1 fragment to a healthy control gen-
otype indicated that this was sufficient for spontaneous
development of sialadenitis. Because of the low sample
number in this group (a result of difficulties with the breeding
of the congenic animals) the increase was not significant.
However, this trend was supported by observations reported
by Johansson and coworkers [15] in an F2 intercross, in which
only the Nss1 locus was associated with sialadenitis and not
the Idd5 locus.
To reproduce the Idd5 locus, as indicated by Brayer and cow-
orkers [16], we made double congenics in which the Idd5
congenic fragment was introgressed on the B10.Q.Nss1
Figure 3
Pathways over-represented in the lists of differentially expressed genes Pathways over-represented in the lists of differentially expressed genes. (a) 'Interferon gamma signalling pathway' in the B10.Q versus B10.Q.Nss1 
gene list; (b) 'Toll-like receptor signalling pathway'; and (c) 'Inflammation mediated by chemokine and cytokine signalling pathway' in the B10.Q ver-
sus B10.Q.Nss1/Idd5 gene list. The coloured boxes represent the genes present in our gene list, and the colours indicate fold change (FC), where 
positive FC indicates upregulation in the congenic mice. Red and blue genes have FC above 2 and FC below -2, respectively. Orange and green 
have FC from 1.5 to 2 and -2 to -1.5, respectively. Yellow and light blue are upregulated and downregulated, respectively, with FC < 1.5.Arthritis Research & Therapy    Vol 9 No 5    Hjelmervik et al.
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strain. In accordance with previous findings [16], we expected
to see enhanced sialadenitis in mice with the homozygosity
but not heterozygosity of Idd5. However, our findings indi-
cated an increase in severity of sialadenitis also in the strain
that was heterozygous for the Idd5 fragment, which might be
explained by dosage dependent increase in SRI values with
the addition of the Idd5 locus. As expected, the most severe
phenotype was seen in the double congenic mice, with both
Nss1 and Idd5 congenic fragments present homozygously.
This implies that the genes within the two fragments may work
synergistically for the development of sialadenitis, and that
expression of possible candidate genes is influenced by the
presence of both fragments.
The congenic breeding strategy enabled us to focus on the
genes within the limits of the NOD loci, which evidently were
causative for the sialadenitis, and to pinpoint the main factors
in the pathogenesis by differential gene expression. We thus
identified several genes within the NOD loci that were differ-
entially expressed in the congenic animals compared with the
healthy controls, and potential candidates that may play a role
in the pathogenesis (Table 2).
In previous studies dissecting AIDs by combining congenic
strains and microarray technology for type 1 diabetes [25] and
collagen-induced arthritis [26], only few differentially
expressed genes have been identified. In our comparison of
the congenic strains with the control strain, as many as 20%
of the expressed genes were identified as being differentially
expressed, and several of these were located in the congenic
fragments. This may be because we used larger congenic
fragments and whole genome microarrays. On the contrary,
when comparing the two congenic strains with each other, we
found that only about 2% of the expressed genes were differ-
entially expressed. This was expected because the two con-
genic strains only differed in the Idd5 locus. However, the
results from the gene expression data are robust, and the gene
graphs illustrate that we were able to identify clear differences
between the strains in each comparison.
The mechanism for onset of SS is as yet unknown, although it
has been hypothesized that exogenous agents such as virus
can precede the vicious circle of chronic inflammation, caus-
ing an induction of type 1 interferons as a defence mechanism
[27]. The expression of type 1 interferon-regulated genes has
been found to be increased in SGs from SS patients in previ-
ous studies [8,9]. Båve and coworkers [11] identified
increased numbers of interferon-α producing cells in SG biop-
sies from SS patients. The present study demonstrates upreg-
ulation of gene expression for Ifnγ  and several interferon-
induced genes and transcription factors, including Stat1, and
Irf1, Irf7, Irf2 and Irf8 in the NOD congenic mice. A study con-
ducted by Cha and colleagues [28] illustrated an important
role for Ifnγ in exocrinopathy, in which neither the NOD Ifnγ null
nor the NOD IfnγR (encoding interferon-γ receptor) null mice
developed sialadenitis or secretory dysfunction, like their NOD
littermates did.
Furthermore, interferon-γ is known to induce Ltb signalling and
expression of chemokines, and to induce the Jak/STAT (Janus
kinase/signal transducer and activator of transcription) signal-
ling pathway by upregulating Stat1 [29], as we reported in this
study. We found Socs1  and  Socs3  to be upregulated,
although suppressor of cytokine signalling (SOCS)1 and
SOCS3 are negative regulators of the Jak/STAT signalling
pathway [29,30]. Socs genes were found to be upregulated in
other autoimmune inflammatory diseases, such as Socs3 in T
cells from the colon mucosa of patients with Crohn's disease
[31] and over-expression of SOCS1, SOCS2 and SOCS3 in
the epidermis of psoriatic skin lesions, as well as in vitro stim-
ulation with interferon-γ induced Socs1 and Socs3 expression
in keratinocytes [32].
That interferons can induce chemokine expression was
reflected in our data. We found numerous chemokines to be
upregulated in the congenic mice (Table 3), such as Ltb, B-cell
activating Cxcl13 and its receptor RANTES (Cxcr5), and T-
cell activating Cxcl12 [7,33], which is consistent with our pre-
vious findings in SS patients [8]. This facilitates the formation
of high endothelial venules and enhances the ability of lym-
phocytes to permeate through the endothelial lining and into
the SG [33]. The reduced gene expression of Ifnz is of interest
because the gene lies in the Nss1 congenic region. The gene
product is known to be inhibitory of B-cell development [34],
and the downregulation of this gene in the double congenic
mice may be related to progression of B-cell development in
the target organ. Monoclonal B-cell proliferation and lym-
phoma development is a common finding in the SGs of pSS
patients [35,36].
We also found up-regulation of the genes encoding the CC
chemokine receptor (CCR)7 and its ligand CC chemokine lig-
and (CCL)19. The ligands CCL19 and CCL21, and their
receptor CCR7 have been found to be involved in homing of
lymphocytes to the target organ [37] and to be localized in the
lymphocytic infiltrates of the synovium in patients with rheuma-
toid arthritis [38]. Studies have been conducted in which Ccr7
deficient mice develop sialadenitis [39]. This is explained by
the lack of central tolerance established in this mouse model.
A most interesting finding reported by Ju and coworkers [40]
indicated upregulation of IRF8 gene expression in dendritic
cells by transforming growth factor-β1, which subsequently
induced CCR7 gene expression. In our study both Irf8 and the
chemokine receptor CCR7 gene, present on T-cells and den-
dritic cells, were found to be upregulated in the congenic
mice; this makes sense, based on the reported presence of
lymphocytic infiltrates in the SG [41].
We found several complement component C1q genes and
Tlr12, located in the congenic fragments, to be upregulated inAvailable online http://arthritis-research.com/content/9/5/R99
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the congenic mice. Stimulation of Toll-like receptors induces
type I interferon production, and plays an important role in SS
[9]. In a recent study, the complement component C1q in
serum from patients with systemic lupus erythematosus was
found to be upregulated, and further upregulated in patients
with active disease [42].
The inflammation is thought to result in SG tissue destruction
and dysfunction in pSS. Therefore, apoptosis has been a
much studied area in pSS research. Studies of apoptosis in
SGs from SS patients have demonstrated increased expres-
sion of the apoptosis inducing Fas and Fas ligand genes [10],
whereas the degree of apoptosis was reduced in the focal infil-
trates and unchanged in the glandular epithelial cells [43,44].
The balance between pro-apoptotic Bax and anti-apoptotic
Bcl2 was found to be crucial for the induction of apoptosis
[43].
In the present study Ifnγ, Fas and Bcl2a1 were found to be
upregulated in the NOD congenic mice, and this is in
accordance with previous findings on apoptosis in pSS
patients [44]. Caspases are fundamental molecules in any
apoptotic pathway. We found several caspases in our gene
lists (Casp1 and Casp11 were upregulated, and Casp7 was
slightly downregulated). Casp3 and Casp6, which are known
to inherit the effector function [45], were not found to be dif-
ferentially expressed.
From the Panther search, we found pathway terms for 'Inflam-
mation mediated by chemokine and cytokine signalling'. This
pathway precedes the induction of cytokine and chemokine
gene expression, which is reflected by the large number of
proinflammatory cytokines and chemokines found to be differ-
entially expressed in the congenic mice.
We were unable to detect any gene expression differences in
the comparison of the two congenic strains heterozygous and
homozygous for Idd5 locus by regular SAM analysis, although
this had much influence on the severity of sialadenitis. How-
ever, by GSEA we identified a set of genes belonging to
'Carbon metabolism' that was enriched between the strains.
This gene set contains several carbonic anhydrase genes that
were downregulated in B10.Q.Nss1/Idd5-ho compared with
B10.Q.Nss1/Idd5-he. Downregulation of carbonic anhy-
drases has also been found associated with pSS [8,46]. The
GSEA found three transcription/translation related gene sets
enriched in B10.Q compared with B10.Q.Nss1, and one
ribosome related gene set enriched in B10.Q.Nss1 compared
with B10.Q. Several gene sets related to immune reactions
were enriched in the congenic mice, although not significantly
so. This method is powerful for achieving high throughput and
unbiased categorization of the gene lists into functional rela-
tionships. However, the method is dependent on the number
of samples in each group [23], which may have been a limiting
factor for utilizing the full potential of GSEA in the present
study.
Conclusion
We set out to identify genes within two regions outside the
MHC region previously identified by quantitative trait locus
mapping as being involved in the development of murine sia-
ladenitis [15,16]. First, we developed a congenic mouse
model that differed genotypically from the control mice only in
two non-MHC loci, namely Nss1  and  Idd5. The two loci
together were sufficient for the congenic mice to develop sia-
ladenitis spontaneously. Furthermore, we have shown that the
loci affect the gene expression profiles in the SGs of the con-
genic mice. The gene expression reflected the congenic frag-
ments. When comparing the gene expression of the
B10.Q.Nss1 and the B10.Q.Nss1/Idd5 congenic strains with
the control strain, several genes within the fragments were
identified as being differentially expressed, especially
cytokines, chemokines and other immunity-related genes.
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